Conference Day Two
Thursday, 27th February
7:50 am Check-In & Morning Coffee
8:50 am Chair’s Opening Remarks
Exploring Investment Trends & Understanding the Investment Landscape to Manage Expectations & Make Cell Therapy More
9:00 am Learning from Successful IPOs & Investments to Understand the Best Way Forward to Increase Investments in Your Company
Synopsis
• Clarifying the reason behind the success of IPOs to ensure success for yourself
• Examining how to increase investments in your company to boost manufacturing and development
• Leveraging learnings to apply what worked and ensure high investments
9:30 am Panel Discussion: Mergers, Acquisitions, Investments: Everything You Need to Know About What the Investors Are Looking For
Synopsis
• Understanding the perspective of investors to understand what they are looking for
• Analysing pharma’s needs to understand how to partner with them
• Having an open dialogue with investors to clarify what you are looking for and how they can help
10.15 Morning Networking Break
Outlining Approaches to Solid Tumours to Improve Efficacy & Durability in Tumour Microenvironment
11:45am: Enhancing TCR-T Cell Potency in Solid Tumours with Next-Generation Toolbox Technologies
• Enabling TCR-T cells to overcome the suppressive tumour
microenvironment
• Augmenting T-cell performance and efficacy
• Reducing exhaustion to improve therapeutic durability
Felix Lorenz, Chief Executive Officer/ Chief Scientific Officer, Captain T Cell
12:15pm: Group Discussion: Validating Novel Targets to Understand the Impact of Cell Therapy on Them & Maximise Safety
• Understanding tumour and target mechanism
• Analysing how to convince the regulators that the novel target
makes sense
• Reviewing the novel target to ensure you are not instigating a
safety signal
12:45pm: Unlocking the Solid Tumour Landscape Through High-Sensitivity CAR-T
• Problem of current (low-sensitivity) CAR constructs
• MatchBio’s proprietary platform for generating of novel high
sensitivity CAR-T
• Application of MatchBio technology to unlock novel CAR-T
targets in solid tumour
Omer Dushek, Founder, MatchBio
1:15pm: Afternoon Break & Poster Session
Outlining Approaches to Solid Tumours to Improve Efficacy & Durability in Tumour Microenvironment
2:15pm: Redesigning CAR Structure to Bridge the Gap & Access Solid Tumours to Improve Efficacy of CAR-T Therapy
• Changing the intrinsic CAR structure to identify solid tumour targets
• Reimagining CAR engineering to make it more sensitive to solid tumour targets
• Translating existing CARs with success in blood tumours to solid tumours
Laurent Poirot, Senior Vice President, Immunology, Cellectis
2:45pm: Exploring Advancements in CAR-T for Solid Tumours
• Overcoming the challenges of the tumour microenvironment
• Utilising the antigen presenting cell functions of gamma delta
cells to elicit a secondary response
• An allogeneic approach
Jeff Liter, Founder & Chief Executive Officer, Luminary Therapeutics
4:00pm: Chimeric ILT-Receptor (CIR™) Allogeneic Technology Effectively Targets HLA-G+ Hematologic & Solid Tumours for Fit-for-Purpose Activation of NK Cells
• CIR™NK cells efficacy and safety in HLAG+ AML, hematologic and solid tumours (animal models data)
• Allogeneic technology to improve patient access and contain manufacturing costs
• Overview of the path to 2 IND with expected FIH clinical trial to start in 2027
Raphaël Ognar, President & Chief Executive Officer, NKILT
Therapeutics
3:45 pm Afternoon Networking Break
Exploring the CAR-TCR Landscape & Understanding the Progress in the Field to Propel Clinical Development
4:30 pm A Landscape Overview of CAR & TCR Therapies
Synopsis
• Reviewing current trends in the CAR and TCR therapy landscape
• Which platform technologies and innovations are developers utilising in an increasingly competitive space?
• Harnessing the insights of Beacon to accelerate the clinical development of your own cell therapy pipeline
5:00 pm Session Reserved for New Clinical Data
5:30 pm Chair’s Closing Remarks
5:35 pm End of Conference
